 Adamis Pharmaceuticals recently provided an update on Tempols Phase IIIII COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes. 